Crescent Biopharma prices $125M public offering of shares and warrants

Crescent Biopharma, Inc. (NASDAQ: CBIO) announced the pricing of an underwritten public offering of 8,094,793 ordinary shares and pre-funded warrants to purchase up to 525,897 ordinary shares, according to a press release.

The ordinary shares are priced at $14.50 per share, while the pre-funded warrants are priced at $14.499 each, reflecting the per-share price minus the $0.001 exercise price. The company expects gross proceeds of approximately $125.0 million before underwriting discounts, commissions, and other offering expenses.

Crescent has also granted underwriters a 30-day option to purchase up to an additional 1,293,103 ordinary shares at the offering price, less underwriting discounts and commissions. All shares and warrants in the offering are being sold by Crescent. The offering is expected to close on July 16, 2026, subject to customary closing conditions.

Jefferies, TD Cowen, Guggenheim Securities, and Cantor are serving as joint book-running managers. LifeSci Capital is acting as passive book-running manager.

The offering is being made pursuant to a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission on July 10, 2026.

You May Also Be Interested In

• OPAL Fuels files S-3 to renew $199M securities registration
• Dorian LPG orders 3 VLGCs, signs $368.4M credit facility
• Clearmind Medicine to acquire 51% of EV wireless charging firm